Skip to main content

Manreet Kanwar

Cardiologist and Professor of Medicine at the University of Chicago, Director of the Heart Failure and Pulmonary Hypertension program and JHLT Deputy Editor.

Sep 4, 2026

10:05
And so can you give us some insight in the factors or the information that you'd like trainees to know about management of respiratory failure with or without positive pressure?
10:16
So, you know, as a cardiologist, I would say the job of the lungs is just to surround the heart.
10:21
No, I'm just kidding.
10:22
So triggers that can throw the RV over the edge, especially an RV that is already struggling, I think are critically important to remember.
10:32
So what does that mean? So let's imagine a patient has pulmonary hypertension.
10:36
Now they are in your ICU because something is triggering acute RV failure or acute and chronic RV failure, depending on circumstances.
10:45
This could be a PE.
13:54
One, is in treating medically hypotension, are there any pH-specific considerations that you take with regard to choice of vasopressor? And part two, is there any role for temporary mechanical circulatory support to bridge these patients through to a definitive therapy?
8:50
What is the impact of publishing in JHLT for colleagues in our field, particularly early career investigators?
8:58
So, you know, I, I look at Journal of Heart and Lung Transplant, of course, it's our official publication for the International Society for Heart and Lung Transplantation, and I would say that it should represent who we are and what we practice.
9:14
So I think of ISHLT, of course, as an international but truly a multidisciplinary society which has the unique advantage of not just focusing on the disease processes of end stage heart and lung disease but also representing, uh, you know, over 50 nations and, uh, almost 20, 25 different specialties.
9:36
So I think our journal is a reflection of our society, and the advantage or the impact of publishing there would be to be, um, recognized and also have a, a channel to present your science that you would present at, let's say, the International Society of Heart and Lung Transplant.
9:56
Of course, not limited to that as well.
9:59
And e- especially for younger colleagues, you know, we ...
10:02
I started my career, my first few publications were in JHLT, and gradually I moved from, you know, uh, being a co-author to maybe the first author and then eventually the senior author, and I see that journey reflected in many, uh, colleagues and friends who've gone through the same, uh, uh, journey as well.
11:35
Is there anything else that we should think about?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.